BioMarin Pharmaceuticals

News

BridgeBio gains on phase 3 dwarfism data

Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.

News

BioMarin ends year with $4.8bn play for Amicus

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.

News

NHS cleared to use AZ's Fasenra for rare autoimmune disease

NICE backs NHS use of an AstraZeneca drug for one rare disease, but says it can't recommend a BioMarin therapy for another.

News

BioMarin starts rebuilding after its downsizing spree

BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.

News

Spruce Bio sows the seeds of its new future

Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.

News

BioMarin's change in direction claims more jobs

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

BridgeBio gains on phase 3 dwarfism data

BioMarin ends year with $4.8bn play for Amicus

NHS cleared to use AZ's Fasenra for rare autoimmune disease

BioMarin starts rebuilding after its downsizing spree

Spruce Bio sows the seeds of its new future

BioMarin's change in direction claims more jobs

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

BioMarin Pharmaceuticals

Editor's Picks